Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · New England Journal of Medicine · 1,957 citations
https://doi.org/10.1056/nejmoa1609709
M
Michelle C. Miller
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
6.8K
Citations
31
h-index
56
i10-index
Michelle C. Miller is an academic researcher from University of Minnesota. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Galectins and Cancer Biology & Glycosylation and Glycoproteins Research. The author has an h-index of 31, co-authored 80 publications.
ORCID: 0000-0002-7860-5785Papers by this author
worksPhase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
2018 · Journal of Clinical Oncology · 1,086 citations
https://doi.org/10.1200/jco.2018.78.9909
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
2020 · Annals of Oncology · 570 citations
https://doi.org/10.1016/j.annonc.2020.11.011
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
2019 · Nature Communications · 383 citations
https://doi.org/10.1038/s41467-019-09068-2
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
2020 · Annals of Oncology · 177 citations
https://doi.org/10.1016/j.annonc.2020.05.001
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
2016 · The Breast · 132 citations
https://doi.org/10.1016/j.breast.2016.06.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat